Evaluation of Repetitive Transcranial Magnetic Stimulation as an Adjunct to Modified Constraint Induced Movement Therapy in Improving Upper Limb Function in Children With Hemiparetic Cerebral Palsy Aged 5 - 18 Years

Hemiparetic Cerebral Palsy Clinical Trial

Official title:

Evaluation of Repetitive Transcranial Magnetic Stimulation as an Adjunct to Modified Constraint Induced Movement Therapy in Improving Upper Limb Function in Children With Hemiparetic Cerebral Palsy Aged 5 - 18 Years - A Randomized Controlled Trial

Clinical Trial Details — Status: Not yet recruiting

Administrative data

• NCT number: NCT03792789
• Other study ID #: IECPG/574/11/2018
• Status: Not yet recruiting
• Phase: N/A
• Start date: January 15, 2019
• Est. completion date: August 30, 2020

Study information

• Verified date: January 2019
• Source: All India Institute of Medical Sciences, New Delhi
• Contact: Sheffali Gulati, MD
• Phone: 09810386847
• Email: sheffaligulati[@]gmail.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators aim to evaluate efficacy of TMS as an adjunct to CIMT, assess its safety and tolerability and study cortical excitability with help of TMS which are both rehabilitative therapies for hemiplegic cerebral palsy.

Description:

Cerebral palsy is the most common motor disability of childhood and Hemiparetic cerebral palsy accounts for about one third of cases. Improving spasticity and upper limb function in these children can lead to better functional outcome and quality of life. TMS is an upcoming rehabilitative modality which has shown promising results in western studies. It has benefits of being non-invasive and has shown to have additive effect when used with CIMT which is standard of care in hemiparetic CP. However, randomized controlled clinical trials comparing it with CIMT alone in hemiparetic CP are very few, none from India so far. The dose, type and duration of TMS and its feasibility in resource limited set up needs to be investigated in children .Therefore, the investigators aim to evaluate efficacy of TMS as an adjunct to CIMT, assess its safety and tolerability and study cortical excitability with help of TMS.

Recruitment information / eligibility

• Status: Not yet recruiting
• Enrollment: 40
• Est. completion date: August 30, 2020
• Est. primary completion date: August 1, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 5 Years to 18 Years

Eligibility

Inclusion Criteria:

• • Age 5 - 18 years

• Hemiparetic Cerebral Palsy (perinatal brain injury)

• Intelligence Quotient >70 (Binet Kamat Test/Malin's Intelligence Scale for Children)

• Modified Ashworth scoring 1-3 for affected limb

• Can sit independently or with support (GMFCS stage : 1-4 and Manual Ability Classification System stage: 1-3)

• Preserved vision and hearing (with or without correction)

Exclusion Criteria:

• • Uncontrolled epilepsy as defined by seizure frequency >1/month for preceding 3 months

• Severe concurrent illness or disease not associated with CP or unstable medical conditions like pneumonia

• Genetic or syndromic associations

• Children diagnosed with Autistic Spectrum Disorders

• Modified Ashworth Scale Score more than 3 at shoulder/elbow/wrist

• Contractures of affected limb

• Severe movement disorder like dystonia, choreo-athetosis or ballismus interfering with purposeful limb movement

• Any congenital brain malformation detected on conventional MRI brain

• Recent surgery/cast/splint in affected limb

• Botulinum toxin/phenol block in affected limb in past 6 months or planned to receive in study period

• Those receiving tone modifying agents within two weeks before enrolment (Tizanidine, baclofen, benzodiazepines, dantrolene)

• mCIMT received in last 6 months

• Any contraindications for TMS - implanted electronic device and non-removable metallic objects near coil e.g. Pacemaker, cochlear implant

Related Conditions & MeSH terms

• Cerebral Palsy
• Hemiparetic Cerebral Palsy

Intervention

Device:
• mCIMT with real rTMS
Modified constraint induced movement therapy will be provided to all children according to predefined protocol. rTMS will be provided using figure of eight shaped coil and TMS stimulator ((Magventure Denmark, X100 with mapoption) over contra-lesional primary motor cortex over 10 sessions of 20 minutes each spread over 4 weeks. Each session will comprise priming ( 10 minutes of 6Hz rTMS at 90% of resting motor threshold, delivered in two trains per minute with 5 seconds per train and 25-seconds intervals between trains (a total of 600 priming pulses)). Priming will be followed immediately by additional 10 minutes of 1Hz rTMS at 90% of resting motor threshold without interruption (a total of 600 low-frequency pulses).
• mCIMT with sham rTMS
Modified constraint induced movement therapy will be provided to all children according to predefined protocol. Sham rTMS will be given using a sham coil.

Locations

Country	Name	City	State
India	India	New Delhi

Sponsors (1)

Lead Sponsor	Collaborator
All India Institute of Medical Sciences, New Delhi

Country where clinical trial is conducted

India, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Efficacy of 4 weeks of mCIMT with sham/real rTMS	? To evaluate the efficacy of repetitive Transcranial Magnetic Stimulation (rTMS) as an adjunct to modified Constraint Induced Movement Therapy (mCIMT) for 4 weeks in improving the Upper Limb Function as per increase in total QUEST score by 5 in 5-18 years old children with Hemiparetic Cerebral Palsy	Within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To evaluate improvement in dissociated movements, grasp, weight bearing and protective extension in each group at the end of 4 weeks	To evaluate improvement in dissociated movements, grasp, weight bearing and protective extension in each group at the end of 4 weeks	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To evaluate improvement in speed of upper limb movements in each group at the end of 4 weeks	To evaluate improvement in speed of upper limb movements in each group at the end of 4 weeks	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To evaluate improvement in muscle strength in each group at the end of 4 weeks	To evaluate improvement in muscle strength in each group at the end of 4 weeks	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To assess improvement in quality of life after the intervention in each group	To assess improvement in quality of life after the intervention in each group	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To assess compliance to therapy in each group by Daily Compliance Log	To assess compliance to therapy in each group by Daily Compliance Log	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To study for adverse events of TMS	To study for adverse events of TMS	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	To evaluate cortical excitability with TMS at baseline and the end of 4 weeks	To evaluate cortical excitability with TMS at baseline and the end of 4 weeks	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS
Secondary	• To evaluate sustenance of improvement by change in QUEST score at the end of 12 weeks, 8 weeks after stopping supervised treatment in both the groups	• To evaluate sustenance of improvement by change in QUEST score at the end of 12 weeks, 8 weeks after stopping supervised treatment in both the groups	within 1 week of end of 4 weeks of mCIMT with sham/real rTMS